Oakbrook Investments LLC Boosts Holdings in PRA Health Sciences Inc (NASDAQ:PRAH)

Oakbrook Investments LLC grew its position in PRA Health Sciences Inc (NASDAQ:PRAH) by 111.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,300 shares of the medical research company’s stock after buying an additional 3,850 shares during the period. Oakbrook Investments LLC’s holdings in PRA Health Sciences were worth $724,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of PRAH. Northern Trust Corp raised its position in PRA Health Sciences by 1.3% during the 4th quarter. Northern Trust Corp now owns 455,410 shares of the medical research company’s stock valued at $41,881,000 after purchasing an additional 6,055 shares during the last quarter. United Services Automobile Association grew its holdings in shares of PRA Health Sciences by 2.4% during the 4th quarter. United Services Automobile Association now owns 17,018 shares of the medical research company’s stock worth $1,565,000 after acquiring an additional 391 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of PRA Health Sciences by 1.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 447,357 shares of the medical research company’s stock worth $41,134,000 after acquiring an additional 6,803 shares during the period. Stifel Financial Corp grew its holdings in shares of PRA Health Sciences by 40.8% during the 4th quarter. Stifel Financial Corp now owns 2,783 shares of the medical research company’s stock worth $258,000 after acquiring an additional 807 shares during the period. Finally, California State Teachers Retirement System grew its holdings in shares of PRA Health Sciences by 3.7% during the 4th quarter. California State Teachers Retirement System now owns 91,047 shares of the medical research company’s stock worth $8,373,000 after acquiring an additional 3,284 shares during the period. 99.65% of the stock is owned by institutional investors and hedge funds.

Shares of PRA Health Sciences stock traded up $0.53 during midday trading on Tuesday, hitting $100.96. The company had a trading volume of 29,661 shares, compared to its average volume of 461,952. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 1.12. The firm has a market cap of $6.53 billion, a PE ratio of 25.69, a P/E/G ratio of 1.34 and a beta of 1.12. The firm has a 50 day moving average price of $96.96. PRA Health Sciences Inc has a 52-week low of $82.12 and a 52-week high of $121.98.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Wednesday, May 1st. The medical research company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.15. PRA Health Sciences had a return on equity of 26.87% and a net margin of 5.50%. The company had revenue of $722.00 million for the quarter, compared to the consensus estimate of $730.84 million. During the same quarter in the prior year, the business posted $0.85 EPS. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. As a group, equities analysts expect that PRA Health Sciences Inc will post 4.63 earnings per share for the current fiscal year.

A number of research firms have weighed in on PRAH. Leerink Swann upgraded AbbVie to a “buy” rating in a report on Tuesday, July 2nd. Svb Leerink reiterated a “market perform” rating on shares of PRA Health Sciences in a report on Tuesday, July 2nd. Mizuho set a $100.00 target price on PRA Health Sciences and gave the stock a “hold” rating in a report on Friday, May 3rd. Wolfe Research began coverage on Iqvia in a report on Tuesday, April 2nd. They set a “market perform” rating on the stock. Finally, ValuEngine upgraded Yandex from a “hold” rating to a “buy” rating in a report on Saturday, April 13th. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the company. PRA Health Sciences has a consensus rating of “Hold” and a consensus price target of $113.00.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

See Also: What is the CBOE Russell 2000® Volatility Index?

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.